IBDEI1DE ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24280,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24280,1,1,0)
 ;;=1^193.
 ;;^UTILITY(U,$J,358.3,24280,1,2,0)
 ;;=2^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,24280,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,24281,0)
 ;;=284.9^^136^1487^4
 ;;^UTILITY(U,$J,358.3,24281,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24281,1,1,0)
 ;;=1^284.9
 ;;^UTILITY(U,$J,358.3,24281,1,2,0)
 ;;=2^APLASTIC ANEMIA NOS
 ;;^UTILITY(U,$J,358.3,24281,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,24282,0)
 ;;=170.9^^136^1487^7
 ;;^UTILITY(U,$J,358.3,24282,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24282,1,1,0)
 ;;=1^170.9
 ;;^UTILITY(U,$J,358.3,24282,1,2,0)
 ;;=2^BONE AND CARTILAGE CANCER,SITE UNSPEC
 ;;^UTILITY(U,$J,358.3,24282,2)
 ;;=^267155
 ;;^UTILITY(U,$J,358.3,24283,0)
 ;;=175.9^^136^1487^10
 ;;^UTILITY(U,$J,358.3,24283,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24283,1,1,0)
 ;;=1^175.9
 ;;^UTILITY(U,$J,358.3,24283,1,2,0)
 ;;=2^BREAST CANCER-MALE,UNSPEC
 ;;^UTILITY(U,$J,358.3,24283,2)
 ;;=^267205
 ;;^UTILITY(U,$J,358.3,24284,0)
 ;;=209.10^^136^1487^37
 ;;^UTILITY(U,$J,358.3,24284,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24284,1,1,0)
 ;;=1^209.10
 ;;^UTILITY(U,$J,358.3,24284,1,2,0)
 ;;=2^MALIG CARCINOID, LARGE INTESTINE
 ;;^UTILITY(U,$J,358.3,24284,2)
 ;;=^336722
 ;;^UTILITY(U,$J,358.3,24285,0)
 ;;=209.29^^136^1487^38
 ;;^UTILITY(U,$J,358.3,24285,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24285,1,1,0)
 ;;=1^209.29
 ;;^UTILITY(U,$J,358.3,24285,1,2,0)
 ;;=2^MALIG CARCINOID,NONBOWEL AND OTH SITE
 ;;^UTILITY(U,$J,358.3,24285,2)
 ;;=^336507
 ;;^UTILITY(U,$J,358.3,24286,0)
 ;;=209.00^^136^1487^39
 ;;^UTILITY(U,$J,358.3,24286,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24286,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,24286,1,2,0)
 ;;=2^MALIG CARCINOID,SMALL INTESTINE
 ;;^UTILITY(U,$J,358.3,24286,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,24287,0)
 ;;=156.9^^136^1487^12
 ;;^UTILITY(U,$J,358.3,24287,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24287,1,1,0)
 ;;=1^156.9
 ;;^UTILITY(U,$J,358.3,24287,1,2,0)
 ;;=2^CHOLANGIOCARCINOMA
 ;;^UTILITY(U,$J,358.3,24287,2)
 ;;=^267102
 ;;^UTILITY(U,$J,358.3,24288,0)
 ;;=286.9^^136^1487^13
 ;;^UTILITY(U,$J,358.3,24288,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24288,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,24288,1,2,0)
 ;;=2^COAGULATION DEFECTS
 ;;^UTILITY(U,$J,358.3,24288,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,24289,0)
 ;;=459.0^^136^1487^20
 ;;^UTILITY(U,$J,358.3,24289,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24289,1,1,0)
 ;;=1^459.0
 ;;^UTILITY(U,$J,358.3,24289,1,2,0)
 ;;=2^HEMORRHAGE NOS
 ;;^UTILITY(U,$J,358.3,24289,2)
 ;;=^55877
 ;;^UTILITY(U,$J,358.3,24290,0)
 ;;=176.9^^136^1487^21
 ;;^UTILITY(U,$J,358.3,24290,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24290,1,1,0)
 ;;=1^176.9
 ;;^UTILITY(U,$J,358.3,24290,1,2,0)
 ;;=2^KAPOSI'S SARCOMA, NOS
 ;;^UTILITY(U,$J,358.3,24290,2)
 ;;=^107993
 ;;^UTILITY(U,$J,358.3,24291,0)
 ;;=161.9^^136^1487^22
 ;;^UTILITY(U,$J,358.3,24291,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24291,1,1,0)
 ;;=1^161.9
 ;;^UTILITY(U,$J,358.3,24291,1,2,0)
 ;;=2^LARYNGEAL CANCER
 ;;^UTILITY(U,$J,358.3,24291,2)
 ;;=^267128
 ;;^UTILITY(U,$J,358.3,24292,0)
 ;;=208.90^^136^1487^23
 ;;^UTILITY(U,$J,358.3,24292,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24292,1,1,0)
 ;;=1^208.90
 ;;^UTILITY(U,$J,358.3,24292,1,2,0)
 ;;=2^LEUKEMIA,UNSP CELL TYPE w/o REM
 ;;^UTILITY(U,$J,358.3,24292,2)
 ;;=^336874
 ;;^UTILITY(U,$J,358.3,24293,0)
 ;;=140.9^^136^1487^25
 ;;^UTILITY(U,$J,358.3,24293,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24293,1,1,0)
 ;;=1^140.9
 ;;^UTILITY(U,$J,358.3,24293,1,2,0)
 ;;=2^LIP CANCER,UNSPEC
 ;;
 ;;$END ROU IBDEI1DE
